U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H18O12
Molecular Weight 462.3604
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SCUTELLARIN

SMILES

O[C@H]1[C@H](OC2=C(O)C(O)=C3C(=O)C=C(OC3=C2)C4=CC=C(O)C=C4)O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O

InChI

InChIKey=DJSISFGPUUYILV-ZFORQUDYSA-N
InChI=1S/C21H18O12/c22-8-3-1-7(2-4-8)10-5-9(23)13-11(31-10)6-12(14(24)15(13)25)32-21-18(28)16(26)17(27)19(33-21)20(29)30/h1-6,16-19,21-22,24-28H,(H,29,30)/t16-,17-,18+,19-,21+/m0/s1

HIDE SMILES / InChI

Description

Scutellarin is the main bioactive component of Breviscapine prepared from the traditional Chinese herb Erilgeron breviscapus (Vant) Hand-Mazz. Scutellarin demonstrated protective effect on cardiovascular and cerebrovascular ischemia. The potential cytoprotective effects of the drug against cerebrovascular ischemia were evidenced by reducing cerebral infarct sizes, ameliorating neurological deficit and inhibiting neuronal apoptosis. Scutellarin is capable of inhibiting I(Na) in neurons through predominantly affecting the inactivated state of I(Na). Scutellarin may alleviate cognitive impairment in a mouse model of hypoxia by promoting proliferation and neuronal differentiation of neural stem cells. Scutellarin might play an therapeutic role by inhibiting oxidative stress and apoptosis in Alzheimer's disease treatment.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
7.1 µM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Single administration of 60 mg of scutellarin.
Route of Administration: Oral
In Vitro Use Guide
100 uM of scutellarin sensitized resveratrol (200 uM) and 5-fluorouracil (500 uM)-evoked apoptosis in p53+/+ but not p53(-/-) cells. Resveratrol- and 5-fluorouracil-elicited caspase-6 activation were promoted by scutellarin in a time-dependent manner. scutellarin itself did not trigger apoptosis or caspase-6 activation at the concentration tested.